Siemens offers PERCIST tool for oncology

Siemens Healthcare's Molecular Imaging division is offering a new quantification tool designed to support PET Response Criteria in Solid Tumors (PERCIST).

PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST).

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment.

The Malvern, PA-based company is highlighting PERCIST this week at the American Society for Radiation Oncology (ASTRO) annual meeting in San Diego.

Related Reading

Siemens celebrates CT milestone, November 2, 2010

Siemens scores $25M Rush contract, October 26, 2010

Siemens targets breast cancer awareness, October 13, 2010

Siemens debuts HD-Chest for PET/CT, October 8, 2010

Siemens launches MRI scanners in U.S., October 7, 2010

Copyright © 2010

Page 1 of 436
Next Page